To standardize and guide the clinical trial design and endpoint selection of drugs for the treatment of advanced non-small cell lung cancer in China, and provide referable technical specifications, NMPA has organized the formulation of and released on September 18, 2019 the Technical Guidelines for Endpoints in Clinical Trials for Advanced Non-Small Cell Lung Cancer.